- MPEP
-
- $40.00
-
2026-06-02
- CAS:96206-92-7
- Purity: 99.54%
- Supply Ability: 10g
|
| Melting point | 45-45.5 °C | | Boiling point | 124.5-126.5 °C(Press: 0.5 Torr) | | density | 1.10±0.1 g/cm3(Predicted) | | storage temp. | Desiccate at +4°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Off-white powder. | | pka | 2.97±0.12(Predicted) | | color | White to Off-White | | Stability: | Light Sensitive | | InChI | 1S/C14H11N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-9H,1H3 | | InChIKey | NEWKHUASLBMWRE-UHFFFAOYSA-N |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| Uses | A potent, subtype selective mGluR5 antagonist | | Uses | 2-Methyl-6-(2-phenylethynyl)pyridine induces pathophysiological mGluR5 signaling in Alzheimer''s disease model mice in sex-selective manner. | | Uses | MPEP is a potent and highly selective non-competitive mGlu5a receptor antagonist (1,2). It is also a positive allosteric modulator at mGlu4 receptors.MPEP exhibits anxiolytic and antidepressant properties that may be applicable for treating schizophrenia (3). | | Definition | ChEBI: 2-methyl-6-(phenylethynyl)pyridine is a methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw. It has a role as a metabotropic glutamate receptor antagonist and an anxiolytic drug. It is a member of methylpyridines and an acetylenic compound. It is a conjugate base of a 2-methyl-6-(phenylethynyl)pyridinium(1+). It derives from a hydride of an acetylene. | | Biological Activity | Potent and highly selective non-competitive antagonist at the mGlu 5 receptor subtype (IC 50 = 36 nM) and a positive allosteric modulator at mGlu 4 receptors. Centrally active following systemic administration in vivo . Reverses mechanical hyperalgesia in the inflamed rat hind paw. Also available as part of the Group I mGlu Receptor Tocriset™ . | | in vivo | MPEP (1-30 mg/kg) induces anxiolytic-like effects in the conflict drinking test and the elevated plus-maze test in rats as well as in the four-plate test in mice[2].
MPEP (1-20 mg/kg) does shorten the immobility time in a tail suspension test in mice, however it is inactive in the behavioural despair test in rats[2].
MPEP (30 mg/kg i.p.) slightly but significantly increases (by 39%) the number of punished crossings in the four-plate test, lower doses of the compound (3 and 10 mg/kg) does not affect the number of punished crossings in that test (F (3,36)=3.240, P<0.05)[2].
MPEP (1, 10 and 20 mg/kg) significantly (by 55% after the highest dose), (F(3,28)=15.47, P<0.001) decreases the immobility time of mice in the tail suspension test. Its efficacy is similar to that of imipramine (20 mg/kg), used as the positive standard[2].
| Animal Model: | Male Wistar rats (200 ± 250 g)[2].
| | Dosage: | IP or PO. | | Administration: | 0.3, 1 and 10 mg/kg, i.p. (Conflict drinking test). | | Result: | At a dose of 0.3 mg/kg was not ffective, at doses of 1 and 10 mg/kg i.p. significantly (F (3,30)=11.193, P<0.001), increased the number of shocks (by 330 and 507%, respectively) accepted during the experimental session in the Vogel test. |
| Animal Model: | Male Wistar rats (200 ± 250 g)[2].
| | Dosage: | IP or PO. | | Administration: | 1, 3 and 10 mg/kg, i.p. or 10 and 30 mg/kg, p.o.(Elevated plus-maze test). | | Result: | Administered at a dose of 1 mg kg71 i.p. did not change the entries into and time spent in the open arms. At doses of 3 and 10 mg/kg i.p. significantly (F (3,24)=22.978, P<0.001) dose-dependently increased the time spent in the open arms (up to 45 and 74%, respectively), and the percentage of entries into the open arms (up to 48 and 68%, respectively, F(3,24)=5.678, P<.01). At doses of 3 and 10 mg/kg i.p. significantly increased (by 64%) the total number of entries and reduced (by about 25%) the total time
spent (data not shown) in the arms (either type).
At the dose of 30 mg/kg (po, but not 10 mg/kg) significantly (up to 64%, F (2,16)=14.249, P<0.001) increased the percentage of the time spent in the open arms and the percentage of entries into the open arms (up to 63%, F (2,16)=7.295, P<0.01). MPEP given p.o. in both doses used did not change the total number of entries nor the total time spent in the arms (either type).
|
| | IC 50 | mGluR5: 36 nM (IC50) | | references | [1] gasparini f, lingenhöhl k, stoehr n, et al. 2-methyl-6-(phenylethynyl)-pyridine (mpep), a potent, selective and systemically active mglu5 receptor antagonist. neuropharmacology, 1999, 38(10): 1493-1503.
[2] tatarczyńska e, kłodzińska a, chojnacka-wójcik e, et al. potential anxiolytic-and antidepressant-like effects of mpep, a potent, selective and systemically active mglu5 receptor antagonist. british journal of pharmacology, 2001, 132(7): 1423-1430. |
| | MPEP Preparation Products And Raw materials |
|